Drug intelligence / Profile preview

KQB726

Development stage: Preclinical
Lead developer: Kumquat Biosciences
Modality: Small Molecules

Overview

KQB726 is a small molecule investigational drug developed by Kumquat Biosciences. It is described as a "KRAS pan" inhibitor, indicating that it targets multiple mutant forms of the KRAS protein, which is frequently mutated in various cancers. The drug is currently in the IND-enabling stage, meaning it is undergoing preclinical development to support an Investigational New Drug (IND) application for entry into human clinical trials. Its primary indication appears to be oncology, specifically targeting cancers driven by KRAS mutations[1].

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on KQB726.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQB726.

Explore the full profile